Jax DiEugenio

FDA Grants Orphan Drug Designation to DPTX3186 in Gastric Cancer

October 30th 2025

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

Dr Wang on the Efficacy of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 30th 2025

Pule Wang, MD, discusses findings from a retrospective study of CNS bridging radiation therapy prior to CAR T-cell therapy in B-cell lymphomas.

ESMO 2025 GI Cancer Data Highlight Emerging Precision Strategies and Treatment Avenues for Rare Cancers

October 30th 2025

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.

Dr Saad on the Importance of Timing When Incorporating Radium-223 Into Prostate Cancer Treatment

October 29th 2025

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29th 2025

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Dr Dreyling on the Evolving Role of BTK Inhibitors in MCL Management

October 29th 2025

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 29th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the design the PSMAddition trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Gupta on Future Directions With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 29th 2025

Shilpa Gupta, MD, discusses future research directions for enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29th 2025

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025

October 29th 2025

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

FDA Grants Breakthrough Device Designation to PlasmaSure for NMIBC

October 28th 2025

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer

October 28th 2025

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC

October 24th 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia

October 24th 2025

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Dr Sweis on the Potential for XmAb819 to Fill Treatment Gaps in Refractory RCC

October 24th 2025

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Dr Peters on Obrixtamig Plus Atezolizumab/Chemo in First-Line ES-SCLC

October 24th 2025

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.

Dr Xie on the Rationale for Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 23rd 2025

Lu Xie, MD, discusses the scientific rationale and clinical development strategy for HS-20093 in the phase 2 ARTEMIS-002 trial.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

Dr Wang on a Retrospective Study of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 23rd 2025

Pule Wang, MD, discusses the design of a retrospective study of CNS bridging radiation therapy prior to CAR T in B-cell lymphomas.

FDA Approval of Y-90 Resin Microspheres Marks a New Chapter for Radioembolization in Unresectable HCC

October 23rd 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.